Corengi tech could enlarge pool of trial subjects

Anyone who's ever browsed ClinicalTrials.gov know that the amount of available data on trials can be overwhelming. For patients not familiar with the clinical trial process, the experience can be even more intimidating, causing them to shy away from trials.

Seattle-based Corengi hopes to change that with technology that could help better match patients with trials. Co-founders Ryan Luce and Eliot Cohen, who unveiled their start-up this week, have launched a site to help Type II diabetes patients navigate confusing inclusion criteria to find the best trials. The system, explains Xconomy, uses a 20-question form to match a patients' medical profile with the correct clinical trial. It further sorts by trial location relative to the patient's home, and allows patients to share their clinical trial experience with other users.

Luce and Cohen are betting that, if enough patients use their service, pharmaceutical and biotech companies will take notice. That could lead to big money as pharma companies attempt to reach patients interested in enrolling in a trial. All the major developers are pursuing new treatments for the massive Type II diabetes market, and a common complaint is the difficulty involved with recruiting the right subjects for new trials. "If you can make it easier for people to understand trials, then you can enlarge the pool," Luce tells Xconomy. "Pharma companies simply can't get enough patients through the door to participate. There's a real business problem there. If you help recruit patients, there's a market there." If the diabetes sit is successful, Corengi could build other sites for disease like rheumatoid arthritis, cancer, and Alzheimer's.

- here's the Xconomy story
- check out Corengi's site

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.